Deep Tech Startups

Product Science provides end-to-end orchestration for decentralized foundation model training, coordinating workloads across geo-distributed, heterogeneous hardware (from general-purpose GPUs to ASICs) with configurable data sovereignty. It serves enterprises, research labs, and public institutions, and previously incubated Gonka, a decentralized network for AI training and inference.

2 investors

ProFound Therapeutics discovers and develops therapeutic candidates by analyzing the expanded human proteome, identifying novel proteins from previously uncharacterized genetic sequences that can serve as drug targets for cancer, immune disorders, and metabolic diseases.

2 investors

Profundus develops an ophthalmic retinal camera that uses Multi Conjugate Adaptive Optics (MCAO) with multiple deformable mirrors to capture high-resolution, wide-field images of the retina. The device resolves retinal features down to a few microns and offers higher resolution and a larger field of view than conventional fundus cameras and single-conjugate adaptive optics systems.</parameter> <parameter name="founders">[]

2 investors

Progressive Robotics develops intelligent, modular robotic palletizing and material handling systems that integrate with major automation ecosystems. The company serves integrators and end-users globally, enabling businesses of any size to deploy advanced automation solutions quickly.

2 investors

Project Q builds Hydris, an Apache 2.0 open-core control plane that integrates heterogeneous sensors, systems, and effectors across air, land, sea, and space into a single taskable picture and exports to any battle management or C2 system. It also offers a UGS Mission Kit for early warning of RF-silent threats, serving defense and sovereign military operations.

2 investors

ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.

2 investors

Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals. Its lead program, PLX-821 (semaglutide), and broader pipeline of dual/triple agonists, amylin-based, and combination therapies are built on this half-life extension delivery architecture.

2 investors

ProMik develops Flash programming and testing solutions for electronics manufacturing, supporting customers from product development through series production. It offers systems and components for in-circuit programming and testing used by electronics manufacturers internationally.

2 investors

ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. The company operates in the biotechnology and neurology therapeutics space.

2 investors

Pronto builds an autonomous haulage system (AHS) that equips haul trucks to operate without a driver, aimed at improving safety, reducing costs, and increasing productivity in off-road and mining environments. The company targets commercial transportation and heavy-haul operations.

2 investors

Prospectral develops next-generation spectral imaging cameras using multimodal and metasurface-mediated sensing for computer vision applications. It combines optical design, semiconductor manufacturing, and computer vision research to build imaging systems for machine perception.

2 investors

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.

2 investors

Proteina develops single-molecule protein-protein interaction (PPI) detection technology (SPID) that generates real-time, high-resolution data to support therapeutic drug development. The company applies PPI analysis toward precision medicine.

2 investors

Proto offers an end-to-end system combining holographic hardware and AI-powered spatial computing to create interactive AI experiences for use in advertising, retail, training, education, healthcare, hospitality, and transportation. The company provides both holoportation devices and software that transforms existing displays into interactive AI agents.

2 investors

Protogon Research designs and deploys autonomous AI systems directly into financial markets through proprietary trading operations. The company leverages machine learning and real market feedback to develop and continuously improve intelligent trading systems.

2 investors

Provolut offers an AI-based web app for protein design that predicts protein evolutions and generates candidate variants from a client's starting dataset, aiming to achieve target protein attributes with far fewer lab experiments than methods like directed evolution or deep mutational scanning. It serves pharma, biotechnology, and research organizations, with on-premises or API deployment options.

2 investors

Proxima is a biotech company developing proximity therapeutics through a drug discovery engine and a structural proteomics data platform.

2 investors

PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery. Its work spans computational chemistry, immunology, and translational research to advance novel therapeutics.

2 investors

STYLY is a spatial layer platform that enables creators to build and distribute digital content for both public spaces and personal environments in the spatial computing era. The platform hosts over 100,000 creators and more than 200,000 pieces of digital content including art, music, fashion, and videos.

2 investors

Psygen is a licensed manufacturer of pharmaceutical-grade psychedelic active pharmaceutical ingredients for academic research, clinical trials, and authorized medical use. The company serves researchers, physicians, and healthcare systems working within regulated compassionate-use and special access programs.

2 investors

Psilocybin biosynthesis platform that produces psychoactive molecular entities using yeast-based technology for pharmaceutical research and drug development.

2 investors

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system. The company pursues its own drug pipeline and partnerships with pharmaceutical companies across drug classes.

2 investors

Pumpkinseed builds a nanophotonic chip platform that reads proteins directly at single-molecule resolution using Raman spectroscopy, generating structured proteomic data. Its technology serves biopharma, biosecurity, and bio-AI applications, aiming to make the proteome readable for drug discovery, biomarker detection, and AI training datasets.

2 investors

Puray is a Munich-based medical technology startup developing medical tubing that uses far-UV photonic disinfection to kill pathogens, including antimicrobial-resistant germs, without harming human tissue. The product aims to prevent device-associated infections, reduce the frequency of tubing replacements, and conserve antibiotics in healthcare settings.

2 investors